FEMARA® (letrozole) has a well-established favorable safety profile in postmenopausal women after adjuvant tamoxifen treatment
FEMARA® is the only AI with demonstrated safety from a large-scale extended adjuvant trial versus placebo1-4
The incidence of the most common (>5% of patients) adverse events seen with FEMARA® were generally comparable vs placebo.1-4
Most frequently reported AEs during chronic therapy (>5% in any group)1
In the MA-17 lipid substudy, effects of FEMARA® were comparable to placebo1,5,6
FEMARA® had no significant effect on total, HDL, and LDL cholesterol, triglycerides, or lipoprotein(a).6
After adjuvant tamoxifen therapy, choose FEMARA® (letrozole) for extended protection accompanied by a favorable safety profile.1-4
To read about the unique efficacy profile of FEMARA® in the initial adjuvant setting, click here.
Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
References: 1. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-1271. 2. Arimidex® (anastrazole) [summary of product characteristics]. Luton, UK: AstraZeneca UK Limited; 2007. 3. Aromasin® (exemestane) [summary of product characteristics]. Sandwich, UK: Pharmacia Ltd; 2008. 4. Jakesz R, Greil R, Gnant M, et al; for the Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845-1853. 5. FEMARA® [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009. 6. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat. 2007;105(suppl 1):45-53.
